|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2000-9-18
|
|
pubmed:abstractText |
Hyperkalemic periodic paralysis (HyperKPP) is an autosomal dominant skeletal muscle disorder caused by single mutations in the SCN4A gene, encoding the human skeletal muscle voltage-gated Na(+) channel. We have now identified one allele with two novel mutations occurring simultaneously in the SCN4A gene. These mutations are found in two distinct families that had symptoms of periodic paralysis and malignant hyperthermia susceptibility. The two nucleotide transitions predict phenylalanine 1490-->leucine and methionine 1493-->isoleucine changes located in the transmembrane segment S5 in the fourth repeat of the alpha-subunit Na(+) channel. Surprisingly, this mutation did not affect fast inactivation parameters. The only defect produced by the double mutant (F1490L-M1493I, expressed in human embryonic kidney 293 cells) is an enhancement of slow inactivation, a unique behavior not seen in the 24 other disease-causing mutations. The behavior observed in these mutant channels demonstrates that manifestation of HyperKPP does not necessarily require disruption of slow inactivation. Our findings may also shed light on the molecular determinants and mechanism of Na(+) channel slow inactivation and help clarify the relationship between Na(+) channel defects and the long-term paralytic attacks experienced by patients with HyperKPP.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/10930446-10227633,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10930446-10366610,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10930446-10465750,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10930446-10564086,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10930446-1316765,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10930446-1338909,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10930446-1659668,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10930446-1659948,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10930446-2340178,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10930446-2443649,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10930446-2443650,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10930446-4705382,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10930446-6209577,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10930446-6270629,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10930446-7689382,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10930446-7809121,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10930446-8161707,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10930446-8382500,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10930446-8388676,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10930446-8575068,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10930446-8618832,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10930446-8804606,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10930446-8842002,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10930446-9083667,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10930446-9138567,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10930446-9336185,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10930446-9339683,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10930446-9503326,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10930446-9508059,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10930446-9929487
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
0021-9738
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
106
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
431-8
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:10930446-Adult,
pubmed-meshheading:10930446-Alleles,
pubmed-meshheading:10930446-Amino Acid Sequence,
pubmed-meshheading:10930446-Base Sequence,
pubmed-meshheading:10930446-Cell Line,
pubmed-meshheading:10930446-DNA Primers,
pubmed-meshheading:10930446-Female,
pubmed-meshheading:10930446-Humans,
pubmed-meshheading:10930446-Ion Channel Gating,
pubmed-meshheading:10930446-Kinetics,
pubmed-meshheading:10930446-Male,
pubmed-meshheading:10930446-Malignant Hyperthermia,
pubmed-meshheading:10930446-Middle Aged,
pubmed-meshheading:10930446-Molecular Sequence Data,
pubmed-meshheading:10930446-Paralyses, Familial Periodic,
pubmed-meshheading:10930446-Point Mutation,
pubmed-meshheading:10930446-Sodium Channel Blockers,
pubmed-meshheading:10930446-Sodium Channels
|
|
pubmed:year |
2000
|
|
pubmed:articleTitle |
A double mutation in families with periodic paralysis defines new aspects of sodium channel slow inactivation.
|
|
pubmed:affiliation |
Howard Hughes Medical Institute, Eccles Institute of Human Genetics, University of Utah, Salt Lake City, Utah 84112, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Case Reports,
Research Support, Non-U.S. Gov't
|
